Patients with heavily pretreated castrate-resistant prostate carcinoma carrying LRP1B mutations had significantly better (75%) and longer response to anti-PD-1 antibody pembrolizumab than non-carriers (14%) [47]. The gene discussed is LRP1B; the disease is prostate carcinoma.